H.C. Wainwright maintains $85 target on Vera Therapeutics stock

Vera Therapeutics (VERA) shares declined after competitor Otsuka released positive Phase 3 data for its IgAN treatment, sibeprenlimab, causing a roughly 30% drop in VERA's stock price; however, H.C. Wainwright reaffirmed its Buy rating and $85 price target, suggesting the market's reaction may be an overreaction given the vast IgAN market and Vera's own positive Phase 3 results for atacicept, which demonstrated a 46% reduction in proteinuria and is on track for a potential 2026 market launch, supported by positive analyst ratings from TD Cowen and JPMorgan.

Analysis

Vera Therapeutics (NASDAQ:VERA) shares experienced a significant downturn, falling approximately 30% after competitor Otsuka announced positive topline data from its Phase 3 VISIONARY study for sibeprenlimab in immunoglobulin A nephropathy (IgAN) on June 6, extending Vera's recent stock decline to over 28% in the past week and more than 52% over the last six months. Despite this market reaction, H.C. Wainwright analyst Arthur He reaffirmed a Buy rating and an $85.00 price target, suggesting the market's response to Otsuka's 51.2% placebo-adjusted UPCR reduction may be an overreaction, given the complexities of cross-trial comparisons and the vast, multi-billion dollar IgAN market capable of supporting multiple products. Vera Therapeutics itself recently reported positive results from its ORIGIN Phase 3 trial of atacicept for IgAN, demonstrating a 46% reduction in proteinuria from baseline and a 42% reduction compared to placebo at week 36. This prompted H.C. Wainwright to raise its target to $85, with TD Cowen also reaffirming a Buy ($60 target) and JPMorgan an Overweight ($68 target), citing data exceeding expectations and a clean safety profile. Evercore ISI maintained an Outperform rating ($75 target), optimistic about an upcoming FDA meeting for accelerated approval. Vera plans a Biologics License Application filing in Q4 2025 for a potential 2026 launch. Financially, Vera maintains strong liquidity with a current ratio of 27.68, and InvestingPro rates its financial health as 'Fair' with strong cash flow management, noting the stock trades near its Fair Value despite recent volatility. Analyst consensus strongly leans towards Buy, with targets ranging from $32 to $100.

Key Decisions for Investors

• Consider the current depressed stock price of Vera Therapeutics as a potential buying opportunity, particularly for those with a long-term horizon, given strong analyst support and the company's positive Phase 3 atacicept data in the large IgAN market.
• Monitor upcoming competitive data releases in the IgAN space and Vera's progress with FDA discussions regarding accelerated approval for atacicept, as well as its planned Biologics License Application filing in Q4 2025.
• Evaluate the company's strong liquidity and 'Fair' financial health rating against the backdrop of significant stock volatility and competitive pressures before making investment decisions, acknowledging the InvestingPro Fair Value suggests current pricing is balanced despite recent declines.